Trial Risk? So I'm curious what the group thinks in terms of how the risk with this patient population can impact the TH1902 trial. While the gettysburg news was encouraging and good to get the word out it did make me wonder how this is accounted for because the patient looked like he was in a rough spot.
Given that part of the entry for the trial is that patients can't have another viable treatment alternative, if there is a death how would that affect the trial and the the share price? I know we haven't seen much appreciation from the oncology platform at all, but I imagine this kind of negative news could have a big impact. But it also seems the patient population is high risk to begin with and that should be taken into consideration.